We are live on !
Find out more
TCM
Tamarack Capital Management Portfolio holdings
AUM
$840M
Turnover
40.48%
1-Year Est. Return
19.47%
This Fund
S&P 500
This Quarter Est. Return
-9.37%
1 Year Est. Return
+19.47%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$840M
AUM Growth
-$29.6M
(-3.4%)
Cap. Flow
-$27.1M
Cap. Flow % of AUM
Cap. Flow %
-3.23%
Top 10 Holdings %
Top 10 Hldgs %
70.69%
Holding
42
New
7
Increased
11
Reduced
10
Closed
10
Avg Time Held
Equity + Options
0.9
years
Top 10 Avg Time Held
Equity + Options
0.8
years
Top 20 Avg Time Held
Equity + Options
0.9
years
Avg Time Held Equity only
1.1
years
Top 10 Avg Time Held Equity only
0.9
years
Top 20 Avg Time Held Equity only
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Patterson Companies, Inc.
PDCO
|
+$17.7M |
| 2 |
Medtronic
MDT
|
+$14.7M |
| 3 |
Amgen
AMGN
|
+$11.8M |
| 4 |
CORI
Corium International, Inc.
CORI
|
+$7.25M |
| 5 |
IMPR
IMPRIVATA, INC COM
IMPR
|
+$7.15M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$17.9M |
| 2 |
MiMedx Group
MDXG
|
+$15.1M |
| 3 |
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
|
+$11.6M |
| 4 |
Bruker
BRKR
|
+$10.2M |
| 5 |
ICU Medical
ICUI
|
+$10.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 56.82% |
| 2 | Miscellaneous | 40.17% |
| 3 | Technology | 3.01% |
| 4 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$819B
| $134M | 15.97% |
700,000
+100,000
| +17% | +$20.3M |
2015 Q1
2 quarters
|
|
2
CALL
iShares 20+ Year Treasury Bond ETF
TLT
$47.9B
| $94.1M | 11.21% |
+762,000
| New | +$92.5M |
2015 Q3
0 quarters
|
|
3
PUT
iShares Russell 2000 ETF
IWM
$77.8B
| $65.5M | 7.8% |
600,000
+100,000
| +20% | +$11.9M |
2015 Q1
2 quarters
|
|
|
4
DELISTED
Patterson Companies, Inc.
PDCO
| $53M | 6.31% |
1,225,000
+370,000
| +43% | +$17.7M |
2014 Q2
5 quarters
|
|
|
ELGX
5
DELISTED
Endologix Inc
ELGX
| $49.7M | 5.91% |
405,000
| – | – |
2014 Q1
6 quarters
|
|
|
6
Medtronic
MDT
$119B
| $46.9M | 5.58% |
700,000
+200,000
| +40% | +$14.7M |
2014 Q3
4 quarters
|
|
7
Quest Diagnostics
DGX
$25.9B
| $43M | 5.12% |
700,000
| – | – |
2014 Q4
3 quarters
|
|
8
Integer Holdings
ITGR
$4.31B
| $39.5M | 4.7% |
767,900
-26,286
| -3% | -$1.31M |
2013 Q2
9 quarters
|
|
|
9
Becton Dickinson
BDX
$51.8B
| $36.5M | 4.34% |
281,875
-128,125
| -31% | -$17.9M |
2014 Q3
4 quarters
|
|
|
NXTM
10
DELISTED
NxStage Medical Inc.
NXTM
| $31.5M | 3.75% |
2,000,000
+325,000
| +19% | +$5.21M |
2013 Q3
8 quarters
|
|
|
MDRX
11
DELISTED
Veradigm Inc. Common Stock
MDRX
| $26.7M | 3.17% |
2,150,000
+375,000
| +21% | +$5.16M |
2014 Q4
3 quarters
|
|
|
IMPR
12
DELISTED
IMPRIVATA, INC COM
IMPR
| $25.3M | 3.01% |
1,425,000
+400,000
| +39% | +$7.15M |
2014 Q2
5 quarters
|
|
13
Alkermes
ALKS
$7.07B
| $21.4M | 2.55% |
365,000
-35,000
| -9% | -$2.31M |
2013 Q2
9 quarters
|
|
14
CALL
Merck
MRK
$359B
| $19.8M | 2.35% |
+419,200
| New | +$22.3M |
2015 Q3
0 quarters
|
|
15
AtriCure
ATRC
$2.83B
| $18.1M | 2.15% |
825,000
-60,000
| -7% | -$1.5M |
2013 Q2
9 quarters
|
|
|
LMNX
16
DELISTED
Luminex Corp
LMNX
| $16.1M | 1.91% |
950,000
-50,000
| -5% | -$904K |
2013 Q4
7 quarters
|
|
17
Bio-Rad Laboratories Class A
BIO
$9.44B
| $14.8M | 1.76% |
110,000
-11,050
| -9% | -$1.59M |
2014 Q2
5 quarters
|
|
18
CALL
Perrigo
PRGO
$2.31B
| $12.6M | 1.5% |
80,000
+27,000
| +51% | +$4.95M |
2015 Q2
1 quarter
|
|
|
CORI
19
DELISTED
Corium International, Inc.
CORI
| $12.4M | 1.47% |
1,325,000
+605,615
| +84% | +$7.25M |
2014 Q2
5 quarters
|
|
20
CALL
Teva Pharmaceutical Industries Limited
TEVA
$48.2B
| $11.3M | 1.34% |
+200,000
| New | +$13M |
2015 Q3
0 quarters
|
|
|
SRGA
21
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $11.1M | 1.32% |
65,000
-1,667
| -3% | -$319K |
2013 Q2
9 quarters
|
|
22
Amarin Corp
AMRN
$244M
| $11M | 1.31% |
285,000
+123,765
| +77% | +$5.62M |
2015 Q2
1 quarter
|
|
|
23
Amgen
AMGN
$232B
| $10.4M | 1.23% |
+75,000
| New | +$11.8M |
2015 Q3
0 quarters
|
|
|
SPNC
24
DELISTED
Spectranetics Corp
SPNC
| $9.26M | 1.1% |
785,000
-265,000
| -25% | -$4.75M |
2013 Q2
9 quarters
|
|
|
25
Perrigo
PRGO
$2.31B
| $7.86M | 0.94% |
50,000
| – | – |
2014 Q4
3 quarters
|
|
Similar funds
GHF
BMCMI
GACM
AH
Tamarack Capital Management's Q3 2015 Portfolio in Review
As of Q3 2015, Tamarack Capital Management held 42 positions worth $840M, down 3.4% from $870M the previous quarter. Its ten largest holdings account for 71% of the portfolio.
Tamarack Capital Management withdrew a net $27.1M in Q3 2015, closing 10 positions and reducing 10 holdings. Its most notable exit was MiMedx Group, an estimated $15.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 64% a quarter earlier, followed by Miscellaneous and Technology.
Against the trend, Tamarack Capital Management opened a new position in Amgen worth $10.4M.
- Tamarack Capital Management's largest Q3 2015 buy was Amgen: 75,000 shares worth $10.4M.
- Tamarack Capital Management added most to Patterson Companies, Inc. in Q3 2015, an estimated $17.7M increase.
- Tamarack Capital Management's biggest Q3 2015 reduction was Becton Dickinson, cutting an estimated $17.9M.
- Tamarack Capital Management fully exited MiMedx Group in Q3 2015, selling an estimated $15.1M.
- Tamarack Capital Management's ten largest holdings make up 71% of its $840M portfolio in Q3 2015.
- Tamarack Capital Management opened 7 new positions and closed 10 in Q3 2015.
- Tamarack Capital Management's portfolio value fell 3.4% quarter-over-quarter to $840M.
Based on Tamarack Capital Management's 13F filing for Q3 2015, filed 10 Nov 2015.